• English
    • magyar
  • English 
    • English
    • magyar
  • Login
View Item 
  •   HuVetA Home
  • Magyar Állatorvosok Lapja
  • 2017
  • View Item
  •   HuVetA Home
  • Magyar Állatorvosok Lapja
  • 2017
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Hazai Mycoplasma bovis törzsek antibiotikum-érzékenységének vizsgálata (bővített másodközlés)

View/Open
MAL 2017 03 169 (1.359Mb)
Date
2017-03
Author
Sulyok, Kinga Mária
Kreizinger, Zsuzsa
Fekete, Lilla
Hrivnák, Veronika
Magyar, Tibor
Jánosi, Szilárd
Schweitzer, Nóra
Turcsányi, Ibolya
Makrai, László
Erdélyi, Károly
Gyuranecz, Miklós
Metadata
Show full item record
Abstract
Summary Background and Objectives: Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The economic losses due to mycoplasma pneumonia could be reduced by antibiotic treatment. Materials and Methods: Minimal inhibitory concentration (MIC) values of 35 M. bovis strains collected from different parts of Hungary were determined by the microbroth dilution method to fifteen antibiotics. Results and Discussion: Strains with high MIC values were found in the case of all applied antibiotics with the exception of pleuromutilins. Our results confirm the observations of increasing MIC values to antibiotics commonly used in the therapy of Mycoplasma infections, primarily to tetracyclines and macrolides. The growth of many M. bovis strains was not inhibited by gentamicin, spectinomycin, florfenicol or lincomycin. Our results emphasize the necessity of systematic testing for antibiotic susceptibility of M. bovis in this geographic region. The most effective antibiotics tested in vitro were fluoroquinolones and pleuromutilins (not registered for cattle) for M. bovis strains in Hungary. However, current antimicrobial usage policies have to be taken into account to avoid further antibiotic resistance development and to reserve fluoroquinolones for the treatment of severe infections which have responded poorly to other classes of antimicrobials.
URI
http://hdl.handle.net/10832/2602
Collections
  • 2017

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 

Browse

All of HuVetACommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

Login

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV